

Sisram Medical (1696.HK) and Fosun Industrial Enter into a Sublicense Agreement for the Commercialization of DaxibotulinumtoxinA (RT002) Injectable

HONG KONG, July 14, 2021 – Sisram Medical Ltd (“Sisram” or “the Company”; 1696.HK), an operational holding company specializing in medical aesthetics technology for wellness, is pleased to announce that its wholly owned subsidiary Sisram Medical (Tianjin) Limited (復銳醫療科技(天津)有限公司) has entered into the Sublicense Agreement with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. (上海復星醫藥產業發展有限公司, referred as “Fosun Industrial”), pursuant to which Fosun Industrial has the right to grant relevant know-hows and patents of Revance’s RT002, so as to, import, use, sell or commercialize RT002 in China mainland, Hong Kong and Macao for the treatment of aesthetic indications (including but not limited to moderate to severe glabellar lines).

Long-lasting neuromodulator botulinum toxin RT002 is a highly efficient and prolonged nerve conduction blocker, developed based on Revance's proprietary technology. RT002 is intended for the treatment of aesthetic indications as well as therapeutic indications. RT002 combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components.

“Adhering to our wellness eco-system strategy, we were scouting for the right botulinum toxin product to join our injectables portfolio. RT002, will further enrich our injectables pipeline and product portfolio, in alignment with our brand values of knowledge, experience and people first. RT002 has been evaluated in the largest aesthetic neuromodulator clinical program ever conducted for the treatment of glabellar (frown) lines. This initiative further promotes the synergy between Sisram’s capital equipment brand, Alma, and Sisram’s injectables activity.” said Lior Dayan, CEO of Sisram Medical.

Mr. Liu Yi, Chairman of Sisram Medical, stated that, “This sublicense agreement between Fosun Industrial and Sisram Medical will further strengthen the Company’s business presence in China. Sisram is committed to expand its portfolio through in-house R&D and external cooperation, and to explore more opportunities in each business units. We will continue to create a collaborative wellness eco-system, then strive to become a pioneer in the global wellness industry.”

###

About Sisram Medical Ltd

Sisram Medical Ltd (1696.HK) is one of the top 5 global leaders in the energy-based medical aesthetics industry. The company is majority held by Fosun Pharma, a leading healthcare group in China. Sisram Medical successfully went public on September 19, 2017, as the first Israeli company listed on the Hong Kong Exchange Main Board. Sisram Medical's core subsidiary, Alma, is a global leading provider of energy-based surgical and medical aesthetics solutions and is active across over 90 countries and jurisdictions worldwide. Flagship systems of Sisram Medical include (i) the "Soprano" family, primarily used for laser hair removal; (ii) the "Harmony" family, a versatile multi-application platform that can be used to treat more than 65 different FDA-cleared indications; (iii) the "Accent" family, primarily used for body contouring and skin tightening; (iv) "FemiLift", a minimally invasive treatment system for various feminine conditions; and (v) "BeautiFill" by LipoFlow platform, the first and only energy-based device cleared by the FDA for autologous fat grafting. In addition, Sisram Medical also entered the injectables market, with products available in Israel, Hong Kong and India.

Sisram Medical – Enhancing Quality of Life.

<http://www.sisram-medical.com>

For media inquiries, please contact:

Ever Bloom (HK) Communications Consultants Group Limited

Orianna Ou / Alex Chen

+852 3468 8171 / 3468 8421

orianna.ou@everbloom.com.cn / alex.chen@everbloom.com.cn